PharmaPoint: Type 2 Diabetes - Current and Future Players

News provided by

Feb 12, 2014, 11:23 ET

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

PharmaPoint: Type 2 Diabetes - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Type 2 Diabetes - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Type 2 Diabetes Market. The report identifies and analyses the key companies shaping and driving the global Type 2 Diabetes market. The report provides insight into the competitive Type 2 Diabetes landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for Type 2 Diabetes
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the Type 2 Diabetes sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the Type 2 Diabetes Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global Type 2 Diabetes market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Market Outlook 15
3.1 Global Markets 15
3.1.1 Forecast 15
3.1.2 Drivers and Barriers - Global Issues 21
4 Current and Future Players 23
4.1 Overview 23
4.2 Trends in Corporate Strategy 26
4.3 Company Profiles 27
4.3.1 Eli Lilly 27
4.3.2 Bristol-Myers Squibb 30
4.3.3 Novo Nordisk 33
4.3.4 Sanofi 36
4.3.5 GlaxoSmithKline 39
4.3.6 AstraZeneca 41
4.3.7 Merck & Co 43
4.3.8 Boehringer Ingelheim 45
4.3.9 Takeda 47
4.3.10 Roche 49
4.3.11 Pfizer 51
4.3.12 Johnson & Johnson 53
5 Appendix 55
5.1 Bibliography 55
5.2 Abbreviations 57
5.3 Methodology 60
5.4 Forecasting Methodology 60
5.4.1 Diagnosed Type 2 Patients 60
5.4.2 Percent Drug-Treated Patients 61
5.4.3 Drugs Included in Each Therapeutic Class 61
5.4.4 Launch and Patent Expiry Dates 62
5.4.5 General Pricing Assumptions 63
5.4.6 Individual Drug Assumptions 64
5.4.7 Generic Erosion 73
5.4.8 Pricing of Pipeline Agents 73
5.5 Physicians and Specialists Included in this Study 75
5.6 About the Authors 77
5.6.1 Analyst II - CVMD 77
5.6.2 Therapy Director - CVMD and Infectious Disease 77
5.6.3 Global Head of Healthcare 78
5.7 About GlobalData 79
5.8 Disclaimer 79

List of Tables

Table 1: Global Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 18
Table 2: Type 2 Diabetes Market - Drivers and Barriers, 2012 21
Table 3: Key Companies in the Type 2 Diabetes Market, 2012 24
Table 4: Other Companies in the Type 2 Diabetes Market, 2012 25
Table 5: Eli Lilly's Type 2 Diabetes Portfolio Assessment, 2013 29
Table 6: Eli Lilly SWOT Analysis, 2012 30
Table 7: Bristol-Myers Squibb's Type 2 Diabetes Portfolio Assessment, 2013 32
Table 8: Bristol-Myers Squibb SWOT Analysis, 2012 33
Table 9: Novo Nordisk's Type 2 Diabetes Portfolio Assessment, 2013 35
Table 10: Novo Nordisk SWOT Analysis, 2012 36
Table 11: Sanofi's Type 2 Diabetes Portfolio Assessment, 2013 38
Table 12: Sanofi SWOT Analysis, 2012 38
Table 13: GSK's Type 2 Diabetes Portfolio Assessment, 2013 40
Table 14: GSK SWOT Analysis, 2012 40
Table 15: AstraZeneca's Type 2 Diabetes Portfolio Assessment, 2013 42
Table 16: AstraZeneca SWOT Analysis, 2012 42
Table 17: Merck's Type 2 Diabetes Portfolio Assessment, 2013 44
Table 18: Merck SWOT Analysis, 2012 44
Table 19: Boehringer Ingelheim's Type 2 Diabetes Portfolio Assessment, 2013 46
Table 20: Boehringer Ingelheim SWOT Analysis, 2012 46
Table 21: Takeda's Type 2 Diabetes Portfolio Assessment, 2013 48
Table 22: Takeda SWOT Analysis, 2012 49
Table 23: Roche's Type 2 Diabetes Portfolio Assessment, 2013 50
Table 24: Roche SWOT Analysis, 2012 50
Table 25: Pfizer's Type 2 Diabetes Portfolio Assessment, 2013 52
Table 26: Pfizer SWOT Analysis, 2012 52
Table 27: J&J's Type 2 Diabetes Portfolio Assessment, 2013 53
Table 28: J&J SWOT Analysis, 2012 54
Table 29: Key Launch Dates 62
Table 30: Key Patent Expiries 62
Table 31: Number of High-Prescribing Physicians Surveyed 76